THE COMORBID CONDITIONS IN RHEUMATOLOGICAL PRACTICE: PARANEOPLASTIC SYNDROME PROBLEM

Zhdan V. M., Volchenko H. V., Babanina M. Y., Tkachenko M. V., Khaimenova H. S.

LITERATURE REVIEWS

Scentific article

The malignant tumor, irrespective of its localization and stage of its development, is capable to provoke complex aggressive autoimmune and metabolic responses. A significant proportion of these are paraneoplastic rheumatic syndromes that «successfully» mimic common rheumatic diseases, sometimes being little different from their typical clinical course. Immune reactions against tumor cells and cross-reactivity between tumor and physiological antigens leads to an autoimmune condition and the formation of a paraneoplastic rheumatic syndrome. The most commonly diagnosed pathology are paraneoplastic rheumatic syndromes, carcinomatous polyarthritis, RS3PEsyndrome, inflammatory myopathy, hypertrophic osteoarthropathy, palmar fasciitis, paniculitis, paraneoplastic vasculitis, polymyalgia rheumatica, scleroderma, secondary gout and lupus-like syndrome. The article presents their characteristics, features of the course and diagnosis, as well as the possibility of symptomatic treatment. The early general clinical symptoms of paraneoplastic rheumatic syndromes before the diagnosis of cancer are presented. The assumption that under commonplace rheumatoid arthritis, scleroderma, generalized inflammatory myopathy or vasculitis masks paraneoplasia is extremely important because it provides an early diagnosis of the malignant disease and greatly increases the chances of successful treatment. Justified suspicion of paraneoplasia, which means intensive tumor search in the early stages, sometimes unsuccessful in unbiased circumstances, helps to avoid unnecessary therapeutic intervention, waste of time and ensure timely treatment of the cancer itself. A clue may be to take into account some aspects of the nature of the debut and the course, at first glance, a common rheumatic disease or syndrome. It is desirable to pay attention to the particular combination of typical rheumatic symptoms in an unexpected combination, the atypical age of the patient for their occurrence, the unusual nature of the joint syndrome, the significant severity of common complaints such as fatigue, general malaise, rapid weight loss and fever. Extremely high activity of markers of systemic inflammation, especially the rate of ESR and the level of C-reactive protein, as well as refractivity to treatment with glucocorticoids, NSAIDs or drugs of basic therapy should be alert. In cases of intense distal edema of the tissues, palmar or plantar fasciitis, inflammatory lesions of the skin and subcutaneous tissue with ulcers in the absence of involvement of organs, oncological concern should occur already at the first treatment of the patient. To search for a tumor with suspected paraneoplastic syndrome, a sequence of diagnostic procedures is recommended, depending on the probability of tumor localization for a particular variant of its course. There are some specific clinical signaling patterns that are highly likely to be associated with malignancy, such as palmar fasciitis with polyarthritis, RS3PE syndrome or hypertrophic osteoarthropathy, atypical course of rheumatic syndrome with therapeutic refractivity, as well as detection of antibodies to TIF1γ or NXP2 in inflammatory myopathy

paraneoplastic syndrome, rheumatology, hypertrophic osteoarthropathy, polymyalgia rheumatica, palmar fasciitis.

1. Zhdan VM, Volchenko GV, Kitura OY, Babanina MY, Shylkina LM, Tkachenko MV. Problemy revmatychnykh zakhvoriuvan u praktytsi simeinoho likaria. Rannii diahnoz i likuvannia: navchalnyi posibnyk. Poptava: ASMI; 2013. 250 s. [in Ukrainian].
2. Zhdan VM, Ivanickiy IV, Shtompel VY, Zazykina DS, Lebid VH. Problemy revmatychnykh zakhvoriuvan u praktytsi simeinoho likaria. Zahalni pytannia: navchalnyi posibnyk. Poptava: ASMI; 2013. 208 s. [in Ukrainian].
3. Schmalzing M. Paraneoplastic syndromes in rheumatology. Z Rheumatol. 2018;77:309-21.
4. Naranjo L. Paraneoplastic rheumatic syndromes. Iatreia. 2011;24:65-75.
5. Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10:662-70.
6. Manger B, Schett G. Rheumatic paraneoplastic syndromes – a clinical link between malignancy and autoimmunity. Clin Immunol. 2018;186: 67-70.
7. Zupancic M, Annamalai A, Brenneman J, Ranatunga S. Migratory polyarthritis as a paraneoplastic syndrome. J Gen Intern Med. 2008;23:2136-9.
8. Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev. 2008;7:352-8.
9. Olivieri I, Salvarani C, Cantini F. RS3PE syndrome: an overview. Clin Exp Rheumatol. 2000;18:53-5.
10. Nathanson L, Hall T. Introduction: paraneoplastic syndromes. Semin Oncol. 1997;24:265-8.
11. Sandhu N, Zakaria S, Boughey J. Dermatomyositis presenting as a paraneoplastic syndrome due to underlying breast cancer. BMJ Case Rep. 2011;128:127-31.
12. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96-100.
13. Lundberg I, Zong M. Inflammatory muscle disease – etiology and pathogenesis (myositis). Nat Rev Rheumatol. 2011;7:297-306.
14. Segal A, Mackenzie A. Hypertrophic osteoarthropathy: a 10-year retrospective analysis. Semin Arthritis Rheum. 1982;12:220-32.
15. Haroon M, Phelan M. A paraneoplastic case of palmar fasciitis and polyarthritis syndrome. Nat Clin Pract Rheumatol. 2008;4:274-7.
16. Mahoney K, Cayea D, Kay L, Gelber A. A handy clue: palmar fasciitis and polyarthritis syndrome. Am J Med. 2014;127:116-8.
17. Chee C. Panniculitis in a patient presenting with a pancreatic tumour and polyarthritis: a case report. J Med Case Reports. 2009;3:7331.
18. Narváez J, Bianchi M, Santo P, Fuente D, Ríos-Rodriguez V, Bolao F, et al. Pancreatitis, panniculitis, and polyarthritis. Semin Arthritis Rheum. 2010;39:417-23.
19. Solans-Laqué R, Bosch-Gil J, Pérez-Bocanegra C, Selva-O’Callaghan A, Simeón-Aznar C, Vilardell-Tarres M. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol. 2008;35:294-304.
20. Wong S, Newland L, John T, White S. Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report. J Med Case Rep. 2012;6:261.
21. Fortin P. Vasculitides associated with malignancy. Curr Opin Rheum. 1996;8:30-3.
22. Liozon E, Loustaud V, Fauchais AL, Soria P, Ly K, Ouattara B, et al. Concurrent temporal (giant cell) arteritis and malignancy: report of 20 patients with review of the literature. J Rheumatol. 2006;33:1606-14.
23. Shah A, Rosen A. Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol. 2011;23:530-5.
24. Zhdan VM, Tkachenko MV, Volchenko GV, Kitura YM. Otsinka vplyvu alopurynolu na funktsiiu nyrok. Svit medytsyny ta biolohii. 2019;1:51-5. [in Ukrainian].
25. Carsons S. The association of malignancy with rheumatic and connective tissue diseases. Semin Oncol. 1997;24:360-72.

«Bulletin of problems biology and medicine» Issue 4 Part 1 (153), 2019 year, 26-30 pages, index UDK 616-002.77-006

10.29254/2077-4214-2019-4-1-153-26-30